CTI Biopharma Corp was incorporated in Washington in 1991. It is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer benefit to patients and health care providers. It is currently concentrating its efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, it is primarily focused on commercializing PIXUVRI in select countries in the European Union, or the E.U., for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma, or NHL, and evaluating pacritinib for the treatment of adult patients with myelofibrosis. The Company faces competition from a variety of companies focused on developing oncology drugs. It competes with large pharmaceutical companies and with other specialized biotechnology companies. The Company is subject to extensive regulation by the FDA and other federal, state, and local regulatory agencies.